The global end stage renal disease market was estimated to be USD 112.10 billion in 2023 and is expected to reach at USD 432.94 billion by 2034 with a CAGR of 13.07% during the forecast period 2024-2034. Growing prevalence of end-stage renal disease (ESRD), rising number of patients experiencing kidney failure, increasing availability of technologically advanced products such as low-maintenance dialysis equipment & artificial kidneys, growing demand for home dialysis, surge in incidence of diabetes & hypertension, increasing patient population with renal issues, rising technological advancements in renal failure treatment, well-established healthcare infrastructure, expanding dialysis clinics & treatment centers, and increasing regulatory approval of innovative treatment options for end-stage renal disease are some of the key factors boosting the market growth.
Increasing regulatory approval of innovative treatment options for end-stage renal disease is predicted to boost the market growth during the forecast period. End-stage renal disease is characterized by kidney-related disorders that occur as a result of chronic kidney disease, negatively impacting kidney function. Patients with end-stage renal disease encounter difficulties in effectively clearing waste from the body, leading to elevated levels of electrolytes, fluids, and other waste substances. Treatment options for these patients may include kidney transplantation or dialysis, while others may require conservative care to monitor health and alleviate symptoms for improved well-being. For instance, in January 2023, Boehringer Ingelheim and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has granted approval for a supplemental new drug application for Jardiance tablets. These tablets are under investigation as a potential treatment to reduce the risk of kidney disease progression and cardiovascular-related deaths in adults diagnosed with chronic kidney disease.
By diagnosis, blood test was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the rising awareness of the significance of early detection, leading to more individuals undergoing blood tests to evaluate their kidney health & detect any indications of kidney dysfunction or end-stage renal disease (ESRD), and ongoing research & development efforts. Additionally, imaging test is predicted to grow at the fastest CAGR during the forecast period owing to the increase in technological advancements, growing emphasis on developing innovative diagnostic test products, and rising trend of market players introducing diagnostic services. For instance, in August 2023, Signify Health, a CVS Health subsidiary, has introduced an extensive in-home kidney health assessment to its Diagnostic and Preventive Services portfolio. These new screenings enhance Signify Health's range of services aimed at facilitating early detection, diagnosis, and treatment management for prevalent causes of illness and death among individuals enrolled in Medicare Advantage.
By treatment, dialysis was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the rising occurrence of end-stage renal disease (ESRD) & chronic kidney disease (CKD), expanding patient population opting for peritoneal dialysis or hemodialysis, increased awareness about different kidney failure conditions & unhealthy lifestyles, and surge in market players' efforts to expand. For instance, in September 2022, Cytecare, based in Bengaluru, unveiled a cutting-edge dialysis center for addressing kidney-related illnesses. Through this launch, Cytecare intends to enhance its comprehensive healthcare services approach. Additionally, transplant is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of chronic kidney disease (CKD), growing elderly population, surge in demand for medical advancements in immunosuppressive drugs & surgical techniques, and limited availability of donor organs.
By end-use, hospitals was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the increase in the number of kidney transplantation surgeries for patients with end-stage renal disease (ESRD), rise in the adoption of advanced diagnostic technologies, such as specialized laboratory tests, imaging methods, & interventional procedures, aimed at diagnosing and treating ESRD, and uptick in government initiatives to address this issue. For instance, in March 2022, In celebration of World Kidney Day in Mauritius, the Health Minister inaugurated a Hemodialysis unit at New Souillac, with the presence of a World Health Representative. This new facility is equipped with 22 hemodialysis machines, capable of accommodating approximately 150 patients. Its objective is to enhance the decentralization of kidney disease treatment. Additionally, dialysis centers is predicted to grow at the fastest CAGR during the forecast period owing to the growing patient demand for ESRD diagnosis & management, surge in adoption of advanced dialysis systems.
Asia Pacific region is anticipated for the highest revenue share during the forecast period owing to the numerous government initiatives, growing awareness drives concerning chronic kidney disease (CKD), surge in introduction of technologically advanced products, increase in the diabetic & hypertensive patient population, rising elderly demographic, and growing launch of new, cost-effective products. For instance, in June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) have initiated a pre-pivotal clinical trial by enrolling their first participant to investigate the safety and effectiveness of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. Additionally, North America region is predicted to grow at fastest CAGR during the forecast period owing to the rising frequency of chronic kidney disease (CKD) cases, growing advancements in diagnostic accuracy, increasing lifestyle-related conditions such as cancer, obesity, & heart disease, rising healthcare expenditure, and surge in regulatory approvals for innovative systems. For instance, in April 2022, Fresenius Medical Care revealed that the Versi PD Cycler System has received approval from the US FDA. This advanced portable automated peritoneal dialysis system is now cleared for use in North America.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing regulatory approval of innovative treatment options for end-stage renal disease is predicted to boost the market growth during the forecast period. End-stage renal disease is characterized by kidney-related disorders that occur as a result of chronic kidney disease, negatively impacting kidney function. Patients with end-stage renal disease encounter difficulties in effectively clearing waste from the body, leading to elevated levels of electrolytes, fluids, and other waste substances. Treatment options for these patients may include kidney transplantation or dialysis, while others may require conservative care to monitor health and alleviate symptoms for improved well-being. For instance, in January 2023, Boehringer Ingelheim and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has granted approval for a supplemental new drug application for Jardiance tablets. These tablets are under investigation as a potential treatment to reduce the risk of kidney disease progression and cardiovascular-related deaths in adults diagnosed with chronic kidney disease.
By diagnosis, blood test was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the rising awareness of the significance of early detection, leading to more individuals undergoing blood tests to evaluate their kidney health & detect any indications of kidney dysfunction or end-stage renal disease (ESRD), and ongoing research & development efforts. Additionally, imaging test is predicted to grow at the fastest CAGR during the forecast period owing to the increase in technological advancements, growing emphasis on developing innovative diagnostic test products, and rising trend of market players introducing diagnostic services. For instance, in August 2023, Signify Health, a CVS Health subsidiary, has introduced an extensive in-home kidney health assessment to its Diagnostic and Preventive Services portfolio. These new screenings enhance Signify Health's range of services aimed at facilitating early detection, diagnosis, and treatment management for prevalent causes of illness and death among individuals enrolled in Medicare Advantage.
By treatment, dialysis was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the rising occurrence of end-stage renal disease (ESRD) & chronic kidney disease (CKD), expanding patient population opting for peritoneal dialysis or hemodialysis, increased awareness about different kidney failure conditions & unhealthy lifestyles, and surge in market players' efforts to expand. For instance, in September 2022, Cytecare, based in Bengaluru, unveiled a cutting-edge dialysis center for addressing kidney-related illnesses. Through this launch, Cytecare intends to enhance its comprehensive healthcare services approach. Additionally, transplant is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of chronic kidney disease (CKD), growing elderly population, surge in demand for medical advancements in immunosuppressive drugs & surgical techniques, and limited availability of donor organs.
By end-use, hospitals was the highest revenue-grossing segment in the global end stage renal disease market in 2023 owing to the increase in the number of kidney transplantation surgeries for patients with end-stage renal disease (ESRD), rise in the adoption of advanced diagnostic technologies, such as specialized laboratory tests, imaging methods, & interventional procedures, aimed at diagnosing and treating ESRD, and uptick in government initiatives to address this issue. For instance, in March 2022, In celebration of World Kidney Day in Mauritius, the Health Minister inaugurated a Hemodialysis unit at New Souillac, with the presence of a World Health Representative. This new facility is equipped with 22 hemodialysis machines, capable of accommodating approximately 150 patients. Its objective is to enhance the decentralization of kidney disease treatment. Additionally, dialysis centers is predicted to grow at the fastest CAGR during the forecast period owing to the growing patient demand for ESRD diagnosis & management, surge in adoption of advanced dialysis systems.
Asia Pacific region is anticipated for the highest revenue share during the forecast period owing to the numerous government initiatives, growing awareness drives concerning chronic kidney disease (CKD), surge in introduction of technologically advanced products, increase in the diabetic & hypertensive patient population, rising elderly demographic, and growing launch of new, cost-effective products. For instance, in June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) have initiated a pre-pivotal clinical trial by enrolling their first participant to investigate the safety and effectiveness of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. Additionally, North America region is predicted to grow at fastest CAGR during the forecast period owing to the rising frequency of chronic kidney disease (CKD) cases, growing advancements in diagnostic accuracy, increasing lifestyle-related conditions such as cancer, obesity, & heart disease, rising healthcare expenditure, and surge in regulatory approvals for innovative systems. For instance, in April 2022, Fresenius Medical Care revealed that the Versi PD Cycler System has received approval from the US FDA. This advanced portable automated peritoneal dialysis system is now cleared for use in North America.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Diagnosis, Treatment, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: End Stage Renal Disease Market Report 2023 - 2034
End Stage Renal Disease Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)
- Urine Test
- Blood Test
- Imaging Test
- Others
End Stage Renal Disease Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Transplant
- Dialysis
- Hemodialysis
- Peritoneal Dialysis
- Wearable Artificial Kidney
End Stage Renal Disease Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Dialysis Centers
- Others
End Stage Renal Disease Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. End Stage Renal Disease Market: Diagnosis Estimates & Trend Analysis
8. End Stage Renal Disease Market: Treatment Estimates & Trend Analysis
9. End Stage Renal Disease Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America End Stage Renal Disease Market
12. Europe Global End Stage Renal Disease Market
13. Asia Pacific Global End Stage Renal Disease Market
14. Latin America Global End Stage Renal Disease Market
15. MEA Global End Stage Renal Disease Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- B. Braun Melsungen AG
- Nipro Corp.
- Cantel Medical
- Nikkiso Co. Ltd.
- Fresenius Medical Care AG & Co. KGaA
- Medtronic Plc
- BD
- JMS Co. Ltd.
- Baxter International Inc.
- Asahi Kasei Medical Co. Ltd.
